Alumis draws Outperform at Oppenheimer
Shares of Apple have surged roughly 40% over the past nine months, but one analyst issued a cautious warning that it’s time to tap the brakes ahead of the company’s earnings report set for Thursday.
Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target The firm says OV329’s promise is “quite real” ...
(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...
Apple Inc. was downgraded to perform from outperform at Oppenheimer, in the latest sign of caution building ahead of the ...
British consumers’ appetite for home entertainment reached new heights in 2024, with the sector surpassing £5.1 billion ($6.4 ...
Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform ...
Andres Oppenheimer, a columnist for the "Miami Herald," said the Trump administration is targeting illegal immigrants with ...
U.S. filmmaker Joshua Oppenheimer, now based in Denmark, worries his "home country is perhaps becoming a dictatorship." "It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback